This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A New Anti-Inflammatory Agent in the Treatment of Acute Otolaryngologic Disorders

L. H. TEITEL, MD; S. B. HARRIS, MD; E. A. THOMPSON, MD; B. W. BILLOW, MD

Arch Otolaryngol. 1963;78(1):91-94.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Most acute laryngologic disorders, even when noninfectious in origin, are usually accompanied by the typical signs and symptoms of inflammation. Some reactions of the inflammatory process are desirable responses which enable the body to localize the offending agent, resist infection, and hasten tissue repair. Other responses such as swelling, redness, heat, and cellular infiltration serve only to delay the healing process and cause needless pain and disability.¹ A drug which could reduce these detrimental reactions would constitute a valuable aid in the therapy of inflammatory disorders.

While the antibiotics and sulfonamides are of undisputed value in the treatment of infections, their use is frequently complicated by problems of bacterial resistance, proliferation of nonsusceptible organisms, or specific drug sensitivity.^2-5 The corticosteroids are often dramatically effective in certain severe or intractable inflammatory states but must be used with caution because of the serious systemic effects which may follow. In addition, . . . [Full Text PDF of this Article]

Author Affiliations
WHITE PLAINS, NY; BROOKLYN, NY; NEW YORK

Otolaryngologist, White Plains Hospital, and Associate in Otolaryngology at Grasslands and St. Agnes Hospitals, White Plains, NY (Dr. Teitel); Associate Visiting Physician, Greenpoint Hospital, Brooklyn, NY (Dr. Harris); Attending Physician, Ear, Nose, and Throat Department, Harlem Hospital, New York, NY (Dr. Thompson); Director of Medical Research, Harlem Hospital (Dr. Billow).

Footnotes
Submitted for publication Jan 17, 1963.

Oxyphenbutazone, 1 -ph e n y l-2- (p-hydroxyphenyl)-3, 5-dioxo-4-butylpyrazolidine-monohydrate, brand of Tandearil, Geigy Pharmaceuticals, Ardsley, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?